Link to All Articles

Mar 20 2008, 12:43 PM EST
Takeda Could Shell Out up to $1.5B in Dissolution of Joint Venture with Abbott
Abbott also gains prostate cancer drug, while Takeda keeps peptic ulcer treatment and investigational pipeline.Full Story

Mar 20 2008, 12:36 PM EST
Presidio Buys Rights to XTL's Preclinical HCV Program for $4M Upfront
XTL could receive $104 million upon certain development and commercialization successes.Full Story

Mar 20 2008, 12:38 PM EST
Role for Insulin in Lifespan Discovered
Study published in Cell shows that the hormone inhibits a master gene regulator protein of the Phase 2 detoxification pathway.Full Story

Mar 19 2008, 12:54 PM EST
AstraZeneca Taps Cenix for RNAi Drug Discovery
Cenix will initially focus on finding and validating oncology targets as well as developing a related RNAi dataset.Full Story

Mar 19 2008, 12:55 PM EST
Alkermes Prompted to Restructure with Eli Lilly's Decision to Drop Inhaled Insulin Development
Company is letting go of 18% of its employees, shutting down its MA plant, and could endure up to $25 million in charges.Full Story

Mar 18 2008, 12:48 PM EST
Immune Response Protein Shifts between Two Unrelated Structures
Study in PNAS shows that each shape has a unique role in attracting and activating white blood cells.Full Story

Mar 18 2008, 12:41 PM EST
Prometic Inks Deal with Sartorius Stedim Biotech to Buttress Asian Business
Sartorius Stedim Biotech has become the preferred equipment supplier to ProMetic's licensees.Full Story

Mar 17 2008, 11:51 AM EST
Q Therapeutics Selects Goodwin to Manufacture Purification mAb
The IgM antibody is used in the production of the firm's cell therapy, which is scheduled to enter a Phase I study in 2009 for transverse myelitis.Full Story

Mar 14 2008, 11:40 AM EST
Lilly Pays $7M Upfront for Transition's Diabetic Program
Worldwide, exclusive licensing deal covering gastrin compounds could yield another $130 million in milestones.Full Story

GenEngNews.com